Chronic Constipation: Labs, Causes, and Next Steps

What Exactly Is Chronic Constipation?

Chronic constipation is not simply infrequent bowel movements. The Rome IV consensus, published in 2016 by a multidisciplinary expert panel, defines it as the presence of two or more of the following for at least three months: straining on more than 25% of defecations, lumpy or hard stools on more than 25% of defecations, a sensation of incomplete evacuation, a sensation of anorectal blockage, manual maneuvers needed to support defecation, and fewer than three spontaneous bowel movements per week 1.

Population-based studies place global prevalence at approximately 16% in adults and roughly 33% in adults over age 60 2. Women are affected about twice as often as men.

Rome IV vs. The Old "Three Times a Week" Rule

The older threshold of fewer than three bowel movements per week captures only one dimension of the disorder. Many patients defecate daily yet experience severe straining, hard stools, and a persistent sense of incomplete emptying. Rome IV incorporates those qualitative features, which is why clinicians now use it rather than stool frequency alone 1.

Subtypes That Change Management

Three physiological subtypes drive different treatment decisions.

Normal-transit constipation is the most common form. Colonic transit time is normal on testing, but patients perceive their bowel function as inadequate. Fiber and osmotic laxatives work well here.

Slow-transit constipation involves measurably delayed colonic transit, confirmed by radiopaque marker studies or wireless motility capsule. Secretagogues and prokinetics tend to be more effective than fiber alone in these patients 3.

Defecatory disorders (also called dyssynergic defecation or pelvic floor dysfunction) involve a failure to coordinate the pelvic floor muscles during straining. Biofeedback therapy, not laxatives, is the primary treatment for this subtype 4.

Causes of Chronic Constipation

Chronic constipation is either primary (a functional motility disorder) or secondary to an identifiable underlying cause. Distinguishing the two is the first job of the diagnostic workup.

Secondary Causes to Rule Out First

Several systemic conditions slow colonic motility or impair rectal sensation.

Hypothyroidism is one of the most common reversible causes. A TSH should be part of every initial lab panel. Even subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) can reduce stool frequency 5.

Hypercalcemia reduces smooth muscle contractility in the colon. Serum calcium above 10.5 mg/dL, from hyperparathyroidism, malignancy, or excess supplementation, is an often-overlooked driver 6.

Diabetes mellitus causes autonomic neuropathy that affects gastrointestinal motility at multiple levels. Constipation is reported in 20 to 44% of patients with long-standing diabetes 7.

Parkinson disease, multiple sclerosis, and spinal cord injury each impair the neurological pathways that coordinate defecation.

Medications That Cause or Worsen Constipation

A thorough medication review is mandatory before ordering labs. The following drug classes are well-documented culprits:

• Opioids (mu-receptor agonism reduces peristalsis)
• Calcium-channel blockers (verapamil and diltiazem more than dihydropyridines)
• Anticholinergics (oxybutynin, tricyclic antidepressants, antihistamines)
• Iron supplements
• Aluminum-containing antacids
• Ondansetron (5-HT3 antagonism slows transit)

The American Gastroenterological Association (AGA) 2013 technical review notes that opioid-induced constipation warrants its own treatment algorithm, separate from functional chronic constipation, because standard laxatives are often insufficient 8.

Primary Functional Causes

When secondary causes are excluded, the diagnosis is primary chronic constipation or irritable bowel syndrome with constipation (IBS-C). The distinction matters for prescribing: IBS-C includes significant abdominal pain as a core feature, while chronic idiopathic constipation does not require pain 1.

The Recommended Lab Panel for New-Onset Chronic Constipation

No single test confirms chronic constipation. Labs are ordered to exclude secondary causes. The following panel is supported by the American College of Gastroenterology (ACG) 2021 clinical guideline 9.

Tier 1: Routine Bloodwork

| Test | What It Screens For | |---|---| | TSH | Hypothyroidism | | Serum calcium | Hypercalcemia | | Basic metabolic panel | Hypokalemia, renal dysfunction | | CBC | Iron-deficiency anemia (red flag for colorectal neoplasia) | | Fasting glucose or HbA1c | Diabetes-related dysmotility |

These tests are low-cost and cover the most common reversible causes. A normal Tier 1 panel in a patient under age 50 with no red-flag features supports a clinical diagnosis of primary chronic constipation and allows a trial of empiric therapy without further testing 9.

Tier 2: When Tier 1 Is Normal and Symptoms Persist

If six to eight weeks of first-line therapy fails, or if the symptom pattern suggests a motility or defecatory disorder, the following tests add diagnostic precision.

Colonic transit study: The radiopaque marker test (Sitzmarks protocol, 24 markers ingested, plain abdominal X-ray at 120 hours) is inexpensive and widely available. Retention of more than 20% of markers (roughly 5 markers) at 120 hours confirms slow transit 3. The wireless motility capsule (SmartPill) provides whole-gut transit data and is FDA-cleared for this indication 10.

Anorectal manometry with balloon expulsion test: This combination detects dyssynergic defecation with approximately 85% sensitivity. A patient who cannot expel a 50-mL water-filled balloon within 2 minutes is considered to have a defecatory disorder, and biofeedback is the next step 4.

Defecography (MRI or fluoroscopic): Reserved for patients with suspected structural defects such as rectocele or rectal prolapse that may not be apparent on physical exam.

When to Skip Straight to Colonoscopy

The ACG 2021 guideline recommends colonoscopy without a prior motility workup for any patient presenting with one or more of the following red-flag features 9:

• Rectal bleeding or hematochezia
• Unintentional weight loss of 10 or more pounds
• Iron-deficiency anemia
• Positive fecal immunochemical test (FIT)
• New-onset constipation in a patient over age 50
• Family history of colorectal cancer or inflammatory bowel disease
• A palpable abdominal or rectal mass

Step-Up Treatment Plan

Treatment follows a structured progression from dietary measures through OTC laxatives to prescription agents. The ACG 2021 guideline provides the clearest published framework for this escalation 9.

Step 1: Fiber and Fluid

Dietary fiber supplementation to 25 to 38 grams per day (25 g for women, 38 g for men, per the Dietary Guidelines for Americans) is the recommended starting point for normal-transit constipation. Soluble fiber, specifically psyllium (ispaghula husk), has the strongest evidence. A 2018 meta-analysis of 14 randomized controlled trials found that psyllium increased stool frequency by 1.9 bowel movements per week compared with placebo 11.

Increasing fluid intake to 1.5 to 2 liters per day is reasonable alongside fiber, though fluid alone, without fiber, does not significantly improve constipation 9.

Step 2: Osmotic Laxatives

Polyethylene glycol 3350 (PEG, sold as MiraLax) at 17 grams per day is the preferred osmotic laxative because of its safety profile, low side-effect burden, and consistency of effect. In a randomized trial by DiPalma et al. (N=304), PEG 17 g/day for 6 months was significantly more effective than placebo for increasing complete spontaneous bowel movements, with no serious adverse events 12.

Lactulose is an alternative but causes more bloating and flatulence. Magnesium citrate works faster (typically within 30 minutes to 3 hours) and is appropriate for episodic relief but is not recommended for daily long-term use in patients with renal impairment.

Step 3: Stimulant Laxatives

Bisacodyl 5 to 15 mg at bedtime or senna 17.2 mg at bedtime can be added when osmotic agents provide insufficient relief. Both are well-tolerated for short- to medium-term use. A Cochrane systematic review found bisacodyl and sodium picosulfate significantly improved stool frequency and consistency compared with placebo 13.

The historical concern about "cathartic colon" from long-term stimulant laxative use is not supported by contemporary evidence 13.

Step 4: Prescription Secretagogues

When Steps 1 through 3 fail after 4 to 8 weeks, prescription therapy is appropriate. Three agents have FDA approval for chronic idiopathic constipation (CIC):

Linaclotide (Linzess) 145 mcg once daily, taken 30 minutes before breakfast. In the Phase III trial by Lembo et al. (N=1,276), linaclotide produced a response (defined as 3 or more complete spontaneous bowel movements per week with an increase of 1 or more from baseline) in 21.2% of patients vs. 3.3% placebo (P<0.0001) at week 12 14.

Plecanatide (Trulance) 3 mg once daily. In a Phase III trial by Miner et al. (N=2,639 across two studies), plecanatide met the FDA responder endpoint at a rate of 21.5% vs. 10.2% for placebo (P<0.001) 15.

Prucalopride (Motegrity) 2 mg once daily (1 mg in patients with CrCl <30 mL/min). This is a selective high-affinity 5-HT4 agonist, not a secretagogue, meaning it works by accelerating colonic transit rather than stimulating fluid secretion. In a pooled analysis of four Phase III trials (N=2,484), prucalopride produced 3 or more complete spontaneous bowel movements per week in 28.4% of patients vs. 12.3% placebo 16.

Step 5: Biofeedback for Defecatory Disorders

Patients identified with dyssynergic defecation on anorectal manometry should be referred for biofeedback therapy before escalating laxatives further. A randomized trial by Rao et al. (N=77) showed biofeedback produced symptom improvement in 70% of patients with dyssynergic defecation vs. 23% with standard laxative care alone 4.

Prescribing more laxatives to a patient with pelvic floor dysfunction is unlikely to help and may worsen symptoms by increasing rectal urgency without improving the underlying coordination deficit.

Hormonal and Metabolic Connections Relevant to HealthRX Patients

Patients on hormone therapy, GLP-1 agonists, or testosterone replacement therapy (TRT) face specific constipation-related considerations that rarely appear together in standard gastroenterology guidelines.

GLP-1 Receptor Agonists and Gut Motility

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow gastric emptying and reduce gut motility as part of their mechanism of action. In STEP-1 (N=1,961), constipation was reported in 24.2% of semaglutide 2.4 mg participants vs. 11.1% in the placebo arm 17. Titrating the dose slowly (the approved 4-week titration schedule) reduces but does not eliminate this risk. Patients on GLP-1 agonists with new or worsening constipation should start PEG 17 g/day proactively. If symptoms persist after dose escalation, a brief hold at the prior dose may be warranted before re-escalating.

Testosterone Replacement Therapy

TRT does not directly cause constipation, but the secondary erythrocytosis it can produce elevates serum calcium through increased parathyroid hormone suppression dynamics. Checking a serum calcium as part of TRT monitoring labs is reasonable. More directly, some injectable testosterone formulations use oil-based carriers that, when combined with reduced physical activity in patients with hypogonadism symptoms, may contribute to overall gut sluggishness.

Progesterone in Hormone Therapy

Oral micronized progesterone (Prometrium 100 to 200 mg at bedtime) exerts a mild smooth-muscle relaxant effect via progesterone receptors in the gut wall. Some patients on cyclic or continuous combined HRT report worsened constipation during the progesterone phase of their cycle. Switching to a transdermal or vaginal progesterone delivery route can reduce GI exposure and may improve symptoms without changing systemic hormone levels.

Red Flags That Require Urgent Evaluation

Not all constipation is functional. The following features require colonoscopy or urgent gastroenterology referral, not a fiber prescription.

Rectal bleeding, even a small amount, warrants investigation. Blood in stool should never be attributed to hemorrhoids without first excluding a neoplastic source, particularly in patients over age 45 9.

Unintentional weight loss of 5% or more of body weight over 6 months alongside constipation raises concern for colorectal cancer, pancreatic pathology, or a systemic malignancy affecting gut motility.

A new change in bowel habit in a patient who previously had regular bowel movements, especially when accompanied by pencil-thin stools, suggests a structural lesion narrowing the lumen.

Iron-deficiency anemia without an obvious dietary explanation requires colonoscopy to exclude right-sided colonic pathology, which bleeds occultly before causing visible rectal bleeding 9.

What to Tell Your Clinician at Your First Appointment

Preparation improves the quality of the evaluation. Bring a brief stool diary covering the two weeks before your appointment. The Bristol Stool Form Scale (a validated 7-point scale) gives your clinician objective data: Type 1 (separate hard lumps) and Type 2 (lumpy sausage) indicate slow transit, while Type 3 and 4 indicate normal consistency 18.

Document every medication, supplement, and over-the-counter product you take. Include iron, calcium, and magnesium supplements, all of which affect stool consistency in different directions.

Note any recent life changes: a new opioid prescription after surgery, a hypothyroidism diagnosis, or the start of a GLP-1 agonist. Constipation that began within days to weeks of a medication change is almost certainly drug-related.

The ACG guideline states: "We suggest that clinicians ask patients about stool consistency using a validated tool such as the Bristol Stool Form Scale in addition to stool frequency, as stool consistency may better reflect colonic transit time" 9.